Longitudinal CTCs gene expression analysis on metastatic castration-resistant prostate cancer patients treated with docetaxel reveals new potential prognosis markers
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1573-7276
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Longitudinal CTCs gene expression analysis on metastatic castration-resistant prostate cancer patients treated with docetaxel reveals new potential prognosis markers ; volume:38 ; number:2 ; day:26 ; month:2 ; year:2021 ; pages:239-251 ; date:4.2021
Clinical & experimental metastasis ; 38, Heft 2 (26.2.2021), 239-251, 4.2021
- Urheber
-
Pereira-Veiga, Thais
González-Conde, Miriam
León-Mateos, Luis
Piñeiro-Cid, Roberto
Abuín, Carmen
Muinelo-Romay, Laura
Martínez-Fernández, Mónica
Brea Iglesias, Jenifer
García González, Jorge
Anido, Urbano
Aguín-Losada, Santiago
Cebey, Víctor
Costa, Clotilde
López-López, Rafael
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1007/s10585-021-10075-1
- URN
-
urn:nbn:de:101:1-2021050806553545582898
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 11:01 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Pereira-Veiga, Thais
- González-Conde, Miriam
- León-Mateos, Luis
- Piñeiro-Cid, Roberto
- Abuín, Carmen
- Muinelo-Romay, Laura
- Martínez-Fernández, Mónica
- Brea Iglesias, Jenifer
- García González, Jorge
- Anido, Urbano
- Aguín-Losada, Santiago
- Cebey, Víctor
- Costa, Clotilde
- López-López, Rafael
- SpringerLink (Online service)
Ähnliche Objekte (12)
Safety and survival of docetaxel and cabazitaxel in metastatic castration-resistant prostate cancer
Comparison of docetaxel pharmacokinetics between castration-resistant and hormone-sensitive metastatic prostate cancer patients
Multiple Docetaxel Retreatments Without Prednisone for Metastatic Castration-Resistant Prostate Cancer in the Docetaxel-Only Era: Effects on PSA Kinetics and Survival
Ureter metastatic castration-resistant prostate cancer: a case report
JMJD2A participates in cytoskeletal remodeling to regulate castration-resistant prostate cancer docetaxel resistance
Physician preferences for non-metastatic castration-resistant prostate cancer treatment
Radioligand therapy of metastatic castration-resistant prostate cancer: current approaches
Patient characteristics and overall survival in patients with post-docetaxel metastatic castration-resistant prostate cancer in the community setting
External validation of risk classification in patients with docetaxel-treated castration-resistant prostate cancer
Metastatic Castration-Resistant Prostate Cancer: Advances in Treatment and Symptom Management
Chemotherapy management for unfit patients with metastatic castration-resistant prostate cancer
Metronomic cyclophosphamide for bone marrow carcinomatosis in metastatic castration-resistant prostate cancer
Safety and survival of docetaxel and cabazitaxel in metastatic castration-resistant prostate cancer
Comparison of docetaxel pharmacokinetics between castration-resistant and hormone-sensitive metastatic prostate cancer patients
Multiple Docetaxel Retreatments Without Prednisone for Metastatic Castration-Resistant Prostate Cancer in the Docetaxel-Only Era: Effects on PSA Kinetics and Survival
Ureter metastatic castration-resistant prostate cancer: a case report
JMJD2A participates in cytoskeletal remodeling to regulate castration-resistant prostate cancer docetaxel resistance
Physician preferences for non-metastatic castration-resistant prostate cancer treatment
Radioligand therapy of metastatic castration-resistant prostate cancer: current approaches
Patient characteristics and overall survival in patients with post-docetaxel metastatic castration-resistant prostate cancer in the community setting
External validation of risk classification in patients with docetaxel-treated castration-resistant prostate cancer
Metastatic Castration-Resistant Prostate Cancer: Advances in Treatment and Symptom Management
Chemotherapy management for unfit patients with metastatic castration-resistant prostate cancer
Metronomic cyclophosphamide for bone marrow carcinomatosis in metastatic castration-resistant prostate cancer
Safety and survival of docetaxel and cabazitaxel in metastatic castration-resistant prostate cancer
Comparison of docetaxel pharmacokinetics between castration-resistant and hormone-sensitive metastatic prostate cancer patients
Multiple Docetaxel Retreatments Without Prednisone for Metastatic Castration-Resistant Prostate Cancer in the Docetaxel-Only Era: Effects on PSA Kinetics and Survival
Ureter metastatic castration-resistant prostate cancer: a case report
JMJD2A participates in cytoskeletal remodeling to regulate castration-resistant prostate cancer docetaxel resistance
Physician preferences for non-metastatic castration-resistant prostate cancer treatment
Radioligand therapy of metastatic castration-resistant prostate cancer: current approaches
Patient characteristics and overall survival in patients with post-docetaxel metastatic castration-resistant prostate cancer in the community setting
External validation of risk classification in patients with docetaxel-treated castration-resistant prostate cancer
Metastatic Castration-Resistant Prostate Cancer: Advances in Treatment and Symptom Management
Chemotherapy management for unfit patients with metastatic castration-resistant prostate cancer